In early 2009, Jan Venulet (JV), gratefully agreed to the suggestion by the President of the International Society of Pharmacovigilance (ISoP) to write ‘a chapter or two’ on the earlier periods of pharmacovigilance. The purpose of ISoP’s project, to which several others will also contribute, is ‘to collect the memories of the beginning of pharmacovigilance with the objective to put it on the website for future generations’. The second author, Margaretha HellingBorda (MHB), invited by JV to collaborate on this walk down memory lane of the WHO’s International Drug Monitoring, was also part of the early and formative years, 1968–1975. Our starting point for refreshing our memories was JV’s own library and numbered references from which we selected relevant publications from the 1960s and 1970s and unpublishedWHO documents. Among the latter, one in particular has been a major reference source (seemingly the only existing copy) entitled ‘‘Pilot Research Project for International Drug Monitoring – Assignment Report, 9 January 1968–10 March 1970 by Dr Jan Venulet, Senior Project Officer’’. Apart from the above, together with World Health Assembly (WHA) Resolutions (Appendix 1), our other primary reference sources in writing this paper have been: Presentation at the 25th Anniversary of the World Health Organization’s Programme for International Monitoring by Jan Venulet. In: Proceedings of the XXVIIth CIOMS (Council for International Organizations of Medical Sciences) Conference in Geneva (organized jointly by CIOMS and WHO), 14–15 September 1993. ‘‘Experience with the World Health Organization: International Monitoring of Adverse Reactions to Drugs’’, WHO, Geneva, by Margaretha Helling. In: Tognoni and Vander Kleijn, editors. Clinical Pharmacy and Clinical Pharmacology. Gouveia. Chapter 9, 141–151, 1976. For a further list of references and selected bibliography, see Appendix 2. The following is a brief summary of the history, development, activities, outputs, results and reflections of the formative years, 1968–1975, of the WHO International Drug Monitoring.
Read full abstract